Drug buyer plaintiffs in a putative antitrust class action
accusing Braintree Laboratories Inc. of initiating baseless patent
litigation to block a generic version of the laxative MiraLax asked
a Delaware federal judge Friday to approve a $17.25 million
settlement of direct purchaser claims.
Rochester Drug Cooperative Inc., Louisiana Wholesale Drug Co. and
Meijer Inc. - which bought MiraLax directly from Braintree at what
they claim was an inflated cost - filed a motion Friday asking U.S.
District Judge Sue L. Robinson to certify a class of direct MiraLax
purchasers and grant preliminary approval to a multimillion-dollar
settlement agreement reached Jan. 6.
In their motion filed Friday, the plaintiffs wrote that under a
proposed settlement agreement reached Jan. 6, Braintree will pay
$17.25 million to resolve claims by persons and entities that
purchased MiraLax directly from Braintree between December 2003 and
View the full article